GlassScriptPhysician profile
Adam Land
NPI 1861798621
$5,710.19
in general payments reported to CMS, 2019-2025
23 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $55.43 · 2021: $244 · 2022: $1,666 · 2023: $445 · 2024: $339 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,547.68 | 2022 | |
| Zimmer Biomet Holdings, INC. | $1,485.27 | 2019-2025 | Rosa, Mymobility Platform |
| Stryker Corporation | $1,150.18 | 2019-2024 | N/A, Mako |
| Depuy Synthes Sales INC. | $425.38 | 2021-2024 | Tfn-Advance, Na, Va-Lcp |
| Innovation Technologies INC | $303.87 | 2025 | Irrisept |
| Vertex Pharmaceuticals Incorporated | $124.93 | 2025 | |
| Medacta USA, INC. | $115.00 | 2024 | |
| Curonix LLC | $90.81 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Heron Therapeutics, INC. | $85.71 | 2023 | Zynrelef |
| Bioventus LLC | $84.04 | 2022-2023 | Gelsyn-3 |
| Smith+Nephew, INC. | $64.94 | 2019-2024 | Redapt |
| Ermi LLC | $49.84 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $26.58 | 2022 | |
| Ethicon US, LLC | $25.72 | 2025 | Surgicel Nu-Knit |
| Solventum Corporation | $23.95 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C.Ulta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $16.10 | 2022 | |
| Abbvie INC. | $15.21 | 2021 | |
| Linvatec Corporation | $14.41 | 2023 | Biobrace 23mm |
| Acera Surgical, INC. | $13.52 | 2025 | Restrata Wound Matrix |
| Horizon Therapeutics Plc | $12.86 | 2019 | |
| Molnlycke Health Care US, LLC | $12.35 | 2025 | Mepilex Border Post-Op Ag |
| Almatica Pharma LLC | $12.14 | 2022 | |
| Heraeus Medical, LLC. | $9.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Land listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.